Medicamen Organics IPO

The IPO for Medicamen Organics is a book-built issue amounting to Rs 10.54 crores. This offering consists solely of a fresh issue totaling 31 lakh shares.

The subscription period for the Medicamen Organics IPO starts on June 21, 2024, and ends on June 25, 2024. The share allotment is anticipated to be finalized on Wednesday, June 26, 2024, and the shares are expected to be listed on the NSE SME on Friday, June 28, 2024.

The IPO price range for Medicamen Organics is set between ₹32 and ₹34 per share. Investors must apply for a minimum of 4000 shares per lot, requiring at least ₹136,000 for a retail investment. High Net Worth Individuals (HNIs) must invest in a minimum of 2 lots, or 8,000 shares, which amounts to ₹272,000.

Medicamen Organics IPO Details

Medicamen Organics IPO Lot Size

Medicamen Organics IPO Objectives

The company intends to allocate the Net Proceeds from the Issue to the following purposes:

1. Covering the costs associated with registering products in international markets.
2. Updating the plant and enhancing production capacity.
3. Meeting the company’s working capital needs.
4. General corporate purposes

About Medicamen Organics Limited

Incorporated in 1995, Medicamen Organics Limited specializes in developing, manufacturing, and distributing pharmaceutical dosages, including generic forms such as tablets, capsules, oral liquids, ointments, gels, syrups, suspensions, and dry powders. The company serves both governmental bodies and private entities as a contract and third-party manufacturer.

Medicamen Organics Limited offers an extensive product range of 84 items, encompassing various drug categories such as antibacterial, antidiarrheal, antifungal, antimalarial, antidiabetic, proton pump inhibitors, antihistamines, antihypertensive drugs, lipid preparations, antiparasitics, multivitamin preparations, multimineral, and non-steroidal anti-inflammatory drug (NSAIDs).

Medicamen Organics Limited Financial Information

Medicamen Organics IPO Timeline

Conclusion

Medicamen Organics Limited, established in 1995, is a prominent player in the pharmaceutical industry, specializing in the development, manufacture, and distribution of a wide array of generic pharmaceutical dosages. With a comprehensive product lineup and a robust distribution network across India and several international markets, the company serves both government and private sectors. The upcoming IPO aims to support the company’s growth initiatives, including product registration in international markets, plant upgrades, increased production capacity, working capital needs, and general corporate purposes